Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly

Wouter W de Herder, H Rob Taal, Piet Uitterlinden, Richard A Feelders, Joop A M J L Janssen and Aart-Jan van der Lely

Section of Endocrinology, Department of Internal Medicine, Erasmus MC, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands

(Correspondence should be addressed to W W de Herder; Email: w.w.deherder@erasmusmc.nl)

Abstract

Objectives: To study whether the growth hormone (GH) response after the subcutaneous administration of octreotide (acute octreotide test) has any predictive value for long-term IGF-I normalization with Sandostatin LAR.

Design: Twenty four therapy-naive patients with active acromegaly were studied.

Results: 75% GH decrease in the acute octreotide test predicted long-term IGF-I normalization with Sandostatin LAR in 8/11 (73%) of patients. 3/13 (23%) patients with >75% GH decrease in the acute octreotide test were long-term biochemically controlled with Sandostatin LAR. Using the >75% GH reduction criterion, the sensitivity and specificity of this test for predicting long-term normalization of serum IGF-I with Sandostatin LAR treatment were 73% and 77%, respectively (positive and negative predictive values: 73% and 77%, respectively). 6/8 (75%) patients with GH suppression to levels <1.1 µg/l and 9/16 (56%) patients with GH suppression to levels <2 µg/l in the acute octreotide test showed normalization of serum IGF-I with long-term Sandostatin LAR treatment. The sensitivity and specificity of GH suppression <1.1 µg/l for predicting of the long-term normalization of serum IGF-I with Sandostatin LAR therapy were 55% and 85%, respectively (positive and negative predictive values: 75% and 69%, respectively). The sensitivity and specificity of GH suppression <2 µg/l for predicting of the long-term normalization of serum IGF-I with Sandostatin LAR therapy were 82% and 46%, respectively (positive and negative predictive values: 56% and 75%, respectively).

Conclusion: The acute octreotide is not recommended for clinical decision making with regard to long-term treatment using the long-acting somatostatin analog Sandostatin LAR in acromegaly.

European Journal of Endocrinology 153 67–71

Introduction

Acromegaly is a chronic and debilitating disorder, which is almost uniquely caused by growth hormone (GH) hypersecretion from a pituitary adenoma (1). Serum insulin-like growth factor I (IGF-I) has been used both as a screening tool and as a tool for clinical monitoring of therapeutic response in patients with acromegaly (2).

Historically, pituitary surgery has been used as first-line treatment for acromegaly. With this treatment, cure rates have been the greatest for microadenomas (ranging from 70 to 80%), but for macroadenoma surgery success rates less than 50% have been reported (3).

Nowadays, medical treatment for acromegaly consists of dopamine agonists, somatostatin analogs, GH receptor antagonists or combinations. Long-acting somatostatin analogs are increasingly being appreciated as first-line therapies for active acromegaly especially for those patients in whom an operation will not likely result in complete cure or in those patients with contraindications for operation (4–7). In the past, acute tests have been designed for predicting the long-term response of the tumoral GH secretion to short-acting somatostatin analogs. Whether acute tests adequately predict these long-term responses is debatable (8–10). The potential predictive value of acute tests for the long-term response to long-acting depot formulations of somatostatin analogs has only been studied very recently by Karavitaki and co-workers (11). In their studies, an acute octreotide test was reliable in predicting ‘safe’ GH levels in patients treated with long-acting octreotide (Sandostatin LAR),

DOI: 10.1530/eje.1.01935

Online version via www.eje-online.org
albeit it was less reliable for predicting this on long-acting lanreotide (Somatulin Autogel, or Somatuline LA).

In the present study we have determined whether an acute test using a single subcutaneous dose of octreotide is useful for predicting long-term normalization of serum IGF-I levels with Sandostatin LAR.

Patients and methods

Patients

Twenty four patients (13 females, 11 males, 24–79 years old at diagnosis, mean age at diagnosis 56 years) with active acromegaly were enrolled in these studies. The diagnosis of active acromegaly was made on the basis of typical clinical features and/or non-suppressed GH after an oral glucose load and IGF-I levels above the age- and sex-adjusted reference range of the assay and the presence of a pituitary tumor at neuroradiology. The patients had not previously been treated with somatostatin analogs, nor with dopamine agonists or GH receptor antagonists and were not operated upon nor had received pituitary radiotherapy. They were treated with Sandostatin LAR (Novartis Pharma, Basle, Switzerland) administered intramuscularly in dosages ranging from 10–30 mg every 4 weeks. The dosage was titrated until the maximum dosage of 30 mg Sandostatin LAR per month was reached, or until normalization of serum IGF-I levels was achieved. Patients were maintained on Sandostatin LAR treatment for at least 9 months. All patients gave their informed consent to participate in these studies.

Test protocol and follow-up

Fifty micrograms of octreotide was administered subcutaneously and blood samples were drawn for GH measurements at 15 min before and 15, 45, 105, 165, 225, 285, 345, 405 and 465 min after administration of the drug. On a control day, samples for GH measurements were drawn at the same time intervals, but no drug was administered. The response to octreotide was calculated using the mean of the 45–465 min GH measurements or mean 45–225 min measurements. GH measurements and expressed as percentage of the GH measurements over the same time interval on the control day. As defined previously, a positive GH response in this test had been arbitrarily defined as >75% decrease of the mean 45–465 min or 45–225 min GH levels (12). We also have looked at a less stringent GH decrease amounting to more than 50%. The GH nadir response was also evaluated.

For long-term follow-up, serum IGF-I was used as parameter for biochemical control. Gender- and age-dependent cut-off levels, as supplied by the manufacturers of the assay, were used.

Assays

Serum GH levels were measured by a two-site chemiluminescent immunometric assay (Immulite; Diagnostic Products Corp., Los Angeles, CA, USA) (intra-assay CV 6.0%, inter-assay CV 5.7%). Serum IGF-I levels were measured by a non-extraction immunometric assay supplied by Diagnostic Systems Laboratories Inc. (Webster, TX, USA) (intra-assay CV 3.9%, inter-assay CV 4.2%).

Results

Patients and GH and IGF-I levels

In the 24 patients, basal serum GH levels were 19.0±26.6 µg/l (mean±S.D.), serum GH levels were 18.3±20.2 µg/l (mean±S.D.) in the 45–465 min sampling interval and 18.0±20.2 µg/l (mean±S.D.) in the 45–225 min sampling interval, both on a control day. Mean basal serum IGF-I levels were 153.6 nmol/l. Overall, in 11 out of these 24 patients (46%), serum IGF-I levels normalized with Sandostatin LAR therapy at long-term (>9 months) follow-up.

Acute octreotide test and long-term follow-up

Sampling intervals and GH decrease after octreotide

Eleven of the 24 patients (46%) showed >75% GH decrease in the acute octreotide test within the 45–465 min, or 45–225 min GH sampling intervals. At follow-up, eight out of these 11 patients (73%) showed an adequate suppression of serum IGF-I to levels within the reference range with long-term Sandostatin LAR treatment.

Thirteen out of the 24 patients (54%) did not show >75% GH response in the acute octreotide test. Three out of these 13 patients (23%) showed normalization of serum IGF-I with long-term Sandostatin LAR treatment.

Using the >75% GH reduction criterion, the acute octreotide test had a sensitivity of 73% and a specificity of 77% for predicting long-term normalization of serum IGF-I with Sandostatin LAR treatment. Results were similar for both GH sampling intervals (45–465 min or 45–225 min GH sampling). Using this criterion, the positive predictive value of the acute octreotide test for the long-term normalization of serum IGF-I with Sandostatin LAR treatment was 73% and the negative predictive value was 77% (Table 1).

Nineteen out of the 24 patients (79%) showed >50% decrease in the acute octreotide test within the 45–465 min GH sampling interval and 20 patients (83%) within the 45–225 min GH sampling interval. At follow-up, 11 of these patients (58% of patients with the 45–465 min GH sampling interval, or 55% of patients with the 45–225 min GH sampling interval) showed an adequate suppression of serum
IGF-I to levels within the reference range with Sandostatin LAR.

Five out of the 24 patients (21%) did not show >50% GH decrease in the acute octreotide test within the 45–465 min GH sampling interval and four patients (17%) within the 45–225 min GH sampling interval. None of these patients showed normalization of serum IGF-I with long-term Sandostatin LAR treatment.

Using the >50% GH reduction criterion, the acute octreotide test had a sensitivity of 100% and a specificity of 38% for predicting long-term normalization of serum IGF-I with Sandostatin LAR therapy for the 45–465 min GH sampling period. For the 45–225 min GH sampling period, these values were 100% and 31% respectively. Using this criterion, the positive predictive value of the acute octreotide test for the long-term normalization of serum IGF-I with Sandostatin LAR therapy was 58% for the 45–465 min GH sampling period and 55% for the 45–225 min GH sampling period and the negative predictive value was 100% for both sampling periods (Table 1).

### GH nadir after octreotide

The nadir GH levels in the acute octreotide test were 5.1 ± 11.9 μg/l (mean ± S.D.), range 0.2–58.9 μg/l with a percentage decrease of 74% as compared with baseline GH levels. The time to achieve nadir was 142 ± 99 min (mean ± S.D.).

In the acute octreotide test, GH suppression to levels <1.1 μg/l was achieved in eight out of 24 patients (33%), six out of these eight patients (75%) showed normalization of serum IGF-I with long-term Sandostatin LAR treatment, whereas two (25%) did not. This level of GH suppression (GH < 1.1 μg/l) had a sensitivity of 55% and a specificity of 85% for predicting of the long-term normalization of serum IGF-I with Sandostatin LAR therapy. The positive and negative predictive values were 75% and 56% respectively (Table 1).

Less stringent GH suppression to levels <2 μg/l in the acute octreotide test was achieved in 16 out of 24 patients (66%). Nine out of these 16 patients (56%) showed normalization of serum IGF-I with long-term Sandostatin LAR treatment, whereas seven (44%) did not. This level of GH suppression (GH < 2 μg/l) had a sensitivity of 82% and a specificity of 46% for predicting of the long-term normalization of serum IGF-I with Sandostatin LAR therapy. The positive and negative predictive values were 56% and 75% respectively (Table 1).

### Discussion

Historically, pituitary (sub)total adenomectomy used to be the primary treatment for active acromegaly. In the late sixties and early seventies of the past century, dopamine agonists were introduced for the medical treatment of prolactinomas and GH-secreting adenomas (1, 13). In the early eighties of the same century, octreotide was introduced as medical treatment for acromegaly, either as primary treatment or as adjunctive treatment after unsuccessful surgery. Because of their superiority to dopamine agonists, somatostatin analogs are currently considered as the first-line medical treatment of acromegaly (1, 14, 15). Recently, the GH receptor blocking drug pegvisomant has been introduced for the treatment of those patients with acromegaly who are not responsive to somatostatin analogs or are intolerant to these drugs (16, 17).

Many studies have evaluated the effects of somatostatin analogs in active acromegaly (5, 18–32). The different criteria, which have been used to define the response to medical treatment, make it almost impossible to compare these studies. Also, newer, more sensitive GH and IGF-I assay techniques have been introduced over time. Suppression of GH to levels below 2.5, 2.0 and 1.0 μg/l have been used as criteria for sufficient response to medical treatment (22, 33). In our study, only normalization of serum IGF-I was used as the sole indicator of chronic control with medical treatment.

In previous studies, the long-term efficacy of short-acting and long-acting somatostatin analogs in sufficiently suppressing GH levels and/or normalizing IGF-I levels varied from 38 to 79% (5, 19, 21, 24–32). However, in some of these studies, patients treated with long-acting somatostatin analogs had been selected on the basis of a positive response to short-acting analogs (5, 21, 28). In our series of unselected therapy-naive patients, 46% of patients were controlled with Sandosta-
tin LAR at long-term follow-up, as monitored by normaliza-
tion of serum IGF-I.

In the present study, more than 75% GH suppression in
the acute octreotide test had a sensitivity of 73% and
a specificity of 77% for predicting normalization of
serum IGF-I with Sandostatin LAR therapy (positive
predictive value 73%, negative predictive value 77%).
As could be expected, using less stringent GH suppres-
sion (>50%) in this test resulted in an increased sen-
sitivity but decreased specificity (sensitivity 100%,
specificity 31–38%, positive predictive value 55–
58%, negative predictive value 100%).

Twenty-three percent of patients who demonstrated
<75% GH response, but none of the patients who
demonstrated <50% GH response to the acute adminis-
tration to octreotide long term showed normalization of
serum IGF-I with long-term Sandostatin LAR therapy.

In a study by Colao and co-workers, the sensitivity and
specificity of an acute octreotide test for the long-term con-
trol by subcutaneously administered octreotide were 71% and
55%, respectively (9). In this study, response was
defined as GH-suppression to serum levels <5 μg/l at
follow-up. The positive and negative predictive values for
the acute octreotide test in their study were 53% and
78% respectively (9). In a recent study by Karavitaki
and co-workers, the positive predictive value for an
acute octreotide test for normalization of serum IGF-I
was 60% for Somatuline Autogel, or Somatuline LA and
77% for Sandostatin LAR when suppression of GH levels
in the acute test to <6.05 mU/l and <5.25 mU/l respect-
ively, was used as criterion (11).

The mean nadir GH level in the acute octreotide test
in these studies were 2.5 mU/l (percentage decrease
85%), which compares well with our mean value
amounting to 5.1 μg/l (percentage decrease 74%).
The mean time to achieve GH nadir in the study by
Karavitaki and co-workers was 228 min (11) and
in our studies it was 142 min.

In conclusion, the acute octreotide test generally pre-
dicts the long-term biochemical response to Sandos-
statin LAR. However, also 23% of the patients who
demonstrated less than 75% decrease in GH levels to
the acute administration to octreotide, or 31% of the
patients who did not demonstrate GH suppression to
levels <1.1 μg/l, or 25% of the patients who did not
produce GH suppression to levels <2 μg/l (25%) were
still chronically controlled with Sandostatin LAR.
Like other authors (9), we do not recommend
acute octreotide tests. Whether this recommendation
also holds for acute tests with newer (receptor specific,
or universal) somatostatin analogs cannot be derived
from the present study.

References

1 Melmed S, Casanueva FF, Cavagnini F, Chanson P, Frohman L,
Grossman A, Ho K, Kleinberg D, Lamberts S, Laws E,
Guidelines for acromegaly management. Journal of Clinical En-
docrinology and Metabolism 2002 87 4054–4058.
2 van der Lely AJ, de Herder WW, Janssen JA & Lamberts SW. Acro-
megaly: the significance of serum total and free IGF-I and IGF-
binding protein-3 in diagnosis. The Journal of Endocrinology
3 Melmed S, Jackson I, Kleinberg D & Klibanski A. Current treat-
ment guidelines for acromegaly. Journal of Clinical Endocrinology
and Metabolism 1998 83 2646–2652.
4 Gilbert J, Ketchen M, Kane P, Mason T, Baister E, Manoghan M,
Barr S & Harris PE. The Treatment of De Novo Acromegalic
Patients with Octreotide-LAR: Efficacy, Tolerability and Cardiovas-
5 Bevan JS, Atkinson AB, Bouloux PM, Hanna E, Harris PE, James RA,
McConnell M, Roberts GA, Scanlon ME, Stewart PM, Teasdale E,
Turner HE, Wass JA & Wardlaw JM. Pri-
mary medical therapy for acromegaly: an open, prospective,
multicenter study of the effects of subcutaneous and intramuscular
slow-release octreotide on growth hormone, insulin-like growth
factor-I, and tumor size. Journal of Clinical Endocrinology
and Metabolism 2002 87 4554–4563.
6 Sheppard MC. Primary medical therapy for acromegaly. Clinical
7 Freda PU & Wardlaw SL. Primary medical therapy for acromegaly: a
1390–1392.
8 Lamberts SW, Uitterlinden P, Schuiffl PC & Klip JG. Therapy of
acromegaly with sandostatin: the predictive value of an acute
test, the value of serum somatomedin-C measurements in dose
adjustment and the definition of a biochemical ‘cure’. Clinical
9 Colao A, Ferone D, Lastoria S, Marzullo P, Cerbone G, Di Sarno A,
Longobardi S, Merola B, Salvatore M & Lombardi G. Prediction of
efficacy of octreotide therapy in patients with acromegaly. Journal of Clinical
Endocrinology and Metabolism 1996 81 2356–2362.
10 Pieters GFFM, Smals AGH & Kloppenborg PWC. Long-term
treatment of acromegaly with the somatostatin analogue SMS
1390–1392.
11 Karavitaki N, Botusan I, Radian S, Cuculescu M, Turner HE &
Wass J. The value of an acute octreotide suppression test in pre-
dicting long-term responses to depot somatostatin analogues in
patients with active acromegaly. Clinical Endocrinology 2005 62
282–288.
12 van der Hoek J, de Herder WW, Feelders RA, van der Lely AJ,
Uitterlinden P, Boerin L, Bruns C, Poorn KW, Lewis I,
Weckbecker G, Krahne T, Holland LJ & Lamberts SW. A single
dose comparison of the acute effects between the new somatostatin
analog SOM230 and octreotide in acromegalic patients. Journal of
13 Ferone D, Colao A, van der Lely AJ & Lamberts SW. Pharma-
cotherapy or surgery as primary treatment for acromegaly? Drugs
14 van der Lely AJ, de Herder WW & Lamberts SW. A risk-benefit
assessment of octreotide in the treatment of acromegaly. Drug
Safety 1997 17 317–324.
15 van der Lely AJ, de Herder WW & Lamberts SW. New medical
16 van der Lely AJ, Hutson RK, Trainer PJ, Better GM, Barkan AL,
Katznelson L, Klibanski A, Herman-Bonert V, Melmed S,
Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR,
Johansson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ,
Hackett S, Zib KA, Davis RJ, Scarlett JA & Thorner MO. Long-
term treatment of acromegaly with pegvisomant, a growth hor-
17 Paisley AN, Trainer PJ & Drake WM. The place of pegvisomant in
the acromegaly treatment algorithm. Growth Hormone and IGF


20 Burt MG & Ho KK. Comparison of efficacy and tolerability of somatostatin analogs and other therapies for acromegaly. *Endocrine* 2003 **20** 299–305.


27 Stewart PM, Kane KF, Stewart SE, Lancranjan I & Sheppard MC. Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly. *Journal of Clinical Endocrinology and Metabolism* 1995 **80** 3267–3272.


33 Freda PU. How effective are current therapies for acromegaly? *Growth Hormone and IGF Research* 2003 **13** S144–S151.

Received 28 February 2005
Accepted 22 March 2005